ARCELLX, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 51.54 USD | -0.72% |
|
-1.02% | -7.26% |
| 04-18 | Arcellx Insider Sold Shares Worth $522,260, According to a Recent SEC Filing | MT |
| 04-03 | Arcellx Insider Sold Shares Worth $1,548,887, According to a Recent SEC Filing | MT |
Chart calendar Arcellx, Inc.
059a.wziJ04mmJ-AQHulsYrQhyhtnk52xp03uub5nMYLImGY.jQn-qfqRcYM9KqZBMOFxsn8-wNzZ8i7XgO4NYcan8x-5YMq5u55Dj1RYng~a7fdde50a51c6923493130af455a9e32
Upcoming events on Arcellx, Inc.
Past events on Arcellx, Inc.
| 10/04/2024 17:45 | Needham Healthcare Conference |
| 26/03/2024 17:00 | H.C. Wainwright Cell Therapy Virtual Conference |
| 06/03/2024 19:50 | TD Cowen Health Care Conference |
| 28/02/2024 21:00 | Q4 2023 Earnings Release |
| 12/12/2023 04:00 | American Society of Hematology Meeting |
| 12/12/2023 01:00 | American Society of Hematology Meeting |
| 15/11/2023 18:15 | Stifel Healthcare Conference |
| 13/11/2023 21:00 | Q3 2023 Earnings Release |
| 03/11/2023 16:30 | TD Cowen Fall Oncology Innovation Summit |
| 10/10/2023 | Cell & Gene Meeting on the Mesa Conference |
| 14/08/2023 21:00 | Q2 2023 Earnings Release |
| 13/06/2023 18:00 | Annual General Meeting |
| 08/05/2023 21:00 | Q1 2023 Earnings Release |
| 20/04/2023 18:00 | Canaccord Genuity Horizons In Oncology Virtual Conference |
| 29/03/2023 21:01 | Q4 2022 Earnings Release |
| 28/02/2023 18:00 | H.C. Wainwright Cell Therapy Virtual Conference |
| 16/02/2023 20:00 | SVB Securities Global Biopharma Conference |
| 09/02/2023 16:20 | Guggenheim Oncology Conference |
| 11/12/2022 | American Society of Hematology Meeting - Publication Number: 3313 |
| 11/12/2022 17:00 | American Society of Hematology Meeting |
Annual results
| Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | 0,00 2,14 - | 110 67,3 63.91% | 86,5 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | -64,0 -58,0 -10.32% | -190 -216 12.23% | -87,8 -120 26.62% | -45,7 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -65,0 -59,7 -8.92% | -191 -198 3.16% | -89,9 -135 33.47% | -116 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -32,1 | 0,00 0,00 - | -189 -198 4.48% | -70,0 -121 42.14% | -111 |
|
Net income Million USD | Released Forecast Spread | -32,1 | -65,0 -60,4 -7.53% | -189 -195 3.32% | -70,7 -116 39.02% | -106 |
|
EPS USD | Released Forecast Spread | 0,00 | -146 -13,7 -959.7% | -5,19 -5,23 0.76% | -1,47 -2,42 39.31% | -2,13 |
| Announcement Date | 14/01/22 | 24/03/22 | 29/03/23 | 28/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 2,14 - | 17,9 88,4 -79.73% | 14,3 30,5 -53.15% | 15,0 15,9 -5.83% | 63,1 20,1 213.49% | 20,7 | 19,8 | 20,1 | 20,5 | 15,7 |
|
EBITDA Million USD | Released Forecast Spread | -32,5 -32,9 1.37% | -93,5 -33,3 -180.78% | -39,6 -62,6 36.75% | -30,0 -31,3 4.07% | -29,1 -23,8 -22.3% | -44,4 -4,89 -808.59% | 15,7 -14,3 210.16% | |||||||
|
EBIT Million USD | Released Forecast Spread | -20,7 -14,7 -40.99% | -32,4 -16,0 -102.72% | -32,6 -32,7 0.17% | -93,9 -34,4 -173.03% | -40,0 -43,7 8.5% | -30,5 31,9 -195.37% | -29,6 -10,6 -178.4% | -44,9 -28,9 -55.26% | 15,0 -30,2 149.64% | -31,1 | -33,6 | -35,0 | -39,5 | -42,7 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -32,1 -33,3 3.57% | -92,9 -33,8 -175.02% | -39,0 -44,8 12.91% | -27,0 59,6 -145.34% | -24,1 -5,60 -331.05% | -39,3 -29,7 -32.44% | 20,5 -30,6 166.99% | -27,7 | -29,9 | -31,4 | -35,9 | -38,0 | ||
|
Net income Million USD | Released Forecast Spread | -20,7 -16,1 -28.26% | -32,4 -17,6 -83.82% | -32,1 -32,0 -0.16% | -92,9 -34,5 -169.13% | -39,0 -43,2 9.82% | -27,3 66,4 -141.21% | -23,9 -11,0 -116.66% | -39,3 -23,6 -66.44% | 19,8 -23,7 183.83% | -27,7 | -29,9 | -31,4 | -36,0 | -38,0 |
|
EPS USD | Released Forecast Spread | -39,9 -3,38 -1080.74% | -1,56 -1,10 -41.82% | -0,88 -1,09 19.27% | -2,12 -0,89 -137.76% | -0,76 -0,96 21.07% | -0,58 1,59 -136.45% | -0,50 -0,31 -62.34% | -0,81 -0,54 -49.95% | 0,42 -0,53 179.48% | -0,55 | -0,58 | -0,61 | -0,67 | -0,61 |
| Announcement Date | 24/03/22 | 12/05/22 | 15/08/22 | 14/11/22 | 29/03/23 | 08/05/23 | 14/08/23 | 13/11/23 | 28/02/24 | - | - | - | - | - |
| Today 21:05 | QIAGEN N.V.: Q1 2024 Earnings Release |
| 29/04/2024 | CRISPR THERAPEUTICS AG: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | DYNE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | PROTAGONIST THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | EDITAS MEDICINE, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | AZENTA, INC.: Q2 2024 Earnings Release (Projected) |
| 01/05/2024 11:30 | UNITED THERAPEUTICS CORPORATION: Q1 2024 Earnings Release |
| 01/05/2024 11:30 | BIO-TECHNE CORPORATION: Q3 2024 Earnings Release |
| 01/05/2024 12:00 | ALKERMES PLC: Q1 2024 Earnings Release |
| 01/05/2024 | VIR BIOTECHNOLOGY, INC.: Q1 2024 Earnings Release |
Past sector events for Arcellx, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ACLX Stock
- Calendar Arcellx, Inc.
